Tandem Diabetes Care (TNDM) Gross Profit (2013 - 2026)

Tandem Diabetes Care has reported Gross Profit for 14 years, with the latest figure at $136.8 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 15.52% year-over-year to $136.8 million; the trailing twelve-month figure through Mar 2026 stood at $564.4 million (up 9.95% YoY), and the FY2025 full-year result was $546.0 million, up 11.53% from the prior year.
• Gross Profit for Q1 2026 stood at $136.8 million, down from $167.5 million in the prior quarter.
• The five-year high for Gross Profit was $167.5 million in Q4 2025, with the low at $82.9 million in Q1 2023.
• Historically, Gross Profit has averaged $114.9 million across 5 years, with a median of $112.8 million in 2024.
• Annual changes were most pronounced in 2023 — Gross Profit retreated 19.24% — and 2024, when it soared 68.77%.
• Tandem Diabetes Care's Gross Profit stood at $115.5 million in 2022, then dropped by 19.24% to $93.3 million in 2023, then soared by 68.77% to $157.5 million in 2024, then grew by 6.35% to $167.5 million in 2025, then decreased by 18.32% to $136.8 million in 2026.
• The last three Gross Profit figures came in at $136.8 million (Q1 2026), $167.5 million (Q4 2025), and $134.3 million (Q3 2025), per Business Quant data.